Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, ...
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases, has announced its presentation schedule for May 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results